25 XP   0   0   10

Glenmark Life Sciences Ltd
Buy, Hold or Sell?

Let's analyse Glenmark Life Sciences Ltd together

PenkeI guess you are interested in Glenmark Life Sciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Glenmark Life Sciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Glenmark Life Sciences Ltd

I send you an email if I find something interesting about Glenmark Life Sciences Ltd.

Quick analysis of Glenmark Life Sciences Ltd (30 sec.)










What can you expect buying and holding a share of Glenmark Life Sciences Ltd? (30 sec.)

How much money do you get?

How much money do you get?
INR1.51
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR174.51
Expected worth in 1 year
INR201.90
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR153.37
Return On Investment
20.4%

For what price can you sell your share?

Current Price per Share
INR752.15
Expected price per share
INR666.05 - INR904.20
How sure are you?
50%

1. Valuation of Glenmark Life Sciences Ltd (5 min.)




Live pricePrice per Share (EOD)

INR752.15

Intrinsic Value Per Share

INR185.33 - INR214.75

Total Value Per Share

INR359.83 - INR389.26

2. Growth of Glenmark Life Sciences Ltd (5 min.)




Is Glenmark Life Sciences Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$256.5m$246.5m$10m3.9%

How much money is Glenmark Life Sciences Ltd making?

Current yearPrevious yearGrowGrow %
Making money$56m$50.2m$5.7m10.3%
Net Profit Margin21.6%19.7%--

How much money comes from the company's main activities?

3. Financial Health of Glenmark Life Sciences Ltd (5 min.)




What can you expect buying and holding a share of Glenmark Life Sciences Ltd? (5 min.)

Welcome investor! Glenmark Life Sciences Ltd's management wants to use your money to grow the business. In return you get a share of Glenmark Life Sciences Ltd.

What can you expect buying and holding a share of Glenmark Life Sciences Ltd?

First you should know what it really means to hold a share of Glenmark Life Sciences Ltd. And how you can make/lose money.

Speculation

The Price per Share of Glenmark Life Sciences Ltd is INR752.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Glenmark Life Sciences Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Glenmark Life Sciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR174.51. Based on the TTM, the Book Value Change Per Share is INR6.85 per quarter. Based on the YOY, the Book Value Change Per Share is INR106.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR31.50 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Glenmark Life Sciences Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.460.1%0.460.1%0.410.1%0.380.1%0.380.1%
Usd Book Value Change Per Share0.080.0%0.080.0%1.270.2%0.520.1%0.520.1%
Usd Dividend Per Share0.380.1%0.380.1%0.130.0%0.190.0%0.190.0%
Usd Total Gains Per Share0.460.1%0.460.1%1.400.2%0.710.1%0.710.1%
Usd Price Per Share4.70-4.70-5.51-2.55-2.55-
Price to Earnings Ratio10.28-10.28-13.43-5.93-5.93-
Price-to-Total Gains Ratio10.21-10.21-3.93-7.07-7.07-
Price to Book Ratio2.24-2.24-2.74-1.25-1.25-
Price-to-Total Gains Ratio10.21-10.21-3.93-7.07-7.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.0258
Number of shares110
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.19
Usd Book Value Change Per Share0.080.52
Usd Total Gains Per Share0.460.71
Gains per Quarter (110 shares)50.6178.38
Gains per Year (110 shares)202.45313.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11663619283230304
233372394166461618
3499108596249691932
46651457983339211246
5832181100041611521560
6998217120249913821874
71164253140458216122188
81330289160666518432502
91497325180874820732816
101663362201083223043130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%

Fundamentals of Glenmark Life Sciences Ltd

About Glenmark Life Sciences Ltd

Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited.

Fundamental data was last updated by Penke on 2024-04-13 00:05:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Glenmark Life Sciences Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Glenmark Life Sciences Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 21.6% means that ₹0.22 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Glenmark Life Sciences Ltd:

  • The MRQ is 21.6%. The company is making a huge profit. +2
  • The TTM is 21.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ21.6%TTM21.6%0.0%
TTM21.6%YOY19.7%+1.9%
TTM21.6%5Y20.1%+1.5%
5Y20.1%10Y20.1%0.0%
1.1.2. Return on Assets

Shows how efficient Glenmark Life Sciences Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 17.3% Return on Assets means that Glenmark Life Sciences Ltd generated ₹0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Glenmark Life Sciences Ltd:

  • The MRQ is 17.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 17.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ17.3%TTM17.3%0.0%
TTM17.3%YOY16.9%+0.3%
TTM17.3%5Y17.5%-0.2%
5Y17.5%10Y17.5%0.0%
1.1.3. Return on Equity

Shows how efficient Glenmark Life Sciences Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 21.8% Return on Equity means Glenmark Life Sciences Ltd generated ₹0.22 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Glenmark Life Sciences Ltd:

  • The MRQ is 21.8%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 21.8%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ21.8%TTM21.8%0.0%
TTM21.8%YOY20.4%+1.5%
TTM21.8%5Y41.7%-19.9%
5Y41.7%10Y41.7%0.0%

1.2. Operating Efficiency of Glenmark Life Sciences Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Glenmark Life Sciences Ltd is operating .

  • Measures how much profit Glenmark Life Sciences Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 27.8% means the company generated ₹0.28  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Glenmark Life Sciences Ltd:

  • The MRQ is 27.8%. The company is operating very efficient. +2
  • The TTM is 27.8%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ27.8%TTM27.8%0.0%
TTM27.8%YOY27.3%+0.5%
TTM27.8%5Y28.4%-0.6%
5Y28.4%10Y28.4%0.0%
1.2.2. Operating Ratio

Measures how efficient Glenmark Life Sciences Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.19 means that the operating costs are ₹1.19 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Glenmark Life Sciences Ltd:

  • The MRQ is 1.192. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.192. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.192TTM1.1920.000
TTM1.192YOY1.219-0.027
TTM1.1925Y1.188+0.003
5Y1.18810Y1.1880.000

1.3. Liquidity of Glenmark Life Sciences Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Glenmark Life Sciences Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.67 means the company has ₹3.67 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Glenmark Life Sciences Ltd:

  • The MRQ is 3.668. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.668. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.668TTM3.6680.000
TTM3.668YOY4.595-0.927
TTM3.6685Y2.574+1.094
5Y2.57410Y2.5740.000
1.3.2. Quick Ratio

Measures if Glenmark Life Sciences Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.79 means the company can pay off ₹1.79 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Glenmark Life Sciences Ltd:

  • The MRQ is 1.791. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.791. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.791TTM1.7910.000
TTM1.791YOY1.767+0.023
TTM1.7915Y1.154+0.637
5Y1.15410Y1.1540.000

1.4. Solvency of Glenmark Life Sciences Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Glenmark Life Sciences Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Glenmark Life Sciences Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.21 means that Glenmark Life Sciences Ltd assets are financed with 20.9% credit (debt) and the remaining percentage (100% - 20.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Glenmark Life Sciences Ltd:

  • The MRQ is 0.209. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.209. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.209TTM0.2090.000
TTM0.209YOY0.169+0.040
TTM0.2095Y0.442-0.233
5Y0.44210Y0.4420.000
1.4.2. Debt to Equity Ratio

Measures if Glenmark Life Sciences Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 26.4% means that company has ₹0.26 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Glenmark Life Sciences Ltd:

  • The MRQ is 0.264. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.264. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.264TTM0.2640.000
TTM0.264YOY0.203+0.061
TTM0.2645Y1.354-1.090
5Y1.35410Y1.3540.000

2. Market Valuation of Glenmark Life Sciences Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Glenmark Life Sciences Ltd generates.

  • Above 15 is considered overpriced but always compare Glenmark Life Sciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 10.28 means the investor is paying ₹10.28 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Glenmark Life Sciences Ltd:

  • The EOD is 19.736. Based on the earnings, the company is fair priced.
  • The MRQ is 10.275. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.275. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD19.736MRQ10.275+9.461
MRQ10.275TTM10.2750.000
TTM10.275YOY13.431-3.156
TTM10.2755Y5.927+4.349
5Y5.92710Y5.9270.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Glenmark Life Sciences Ltd:

  • The EOD is 64.353. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 33.505. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 33.505. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD64.353MRQ33.505+30.848
MRQ33.505TTM33.5050.000
TTM33.505YOY12.084+21.421
TTM33.5055Y11.397+22.108
5Y11.39710Y11.3970.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Glenmark Life Sciences Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.24 means the investor is paying ₹2.24 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Glenmark Life Sciences Ltd:

  • The EOD is 4.310. Based on the equity, the company is fair priced.
  • The MRQ is 2.244. Based on the equity, the company is underpriced. +1
  • The TTM is 2.244. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.310MRQ2.244+2.066
MRQ2.244TTM2.2440.000
TTM2.244YOY2.738-0.494
TTM2.2445Y1.245+0.999
5Y1.24510Y1.2450.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Glenmark Life Sciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.8476.8470%106.227-94%43.627-84%43.627-84%
Book Value Per Share--174.509174.5090%167.662+4%109.097+60%109.097+60%
Current Ratio--3.6683.6680%4.595-20%2.574+43%2.574+43%
Debt To Asset Ratio--0.2090.2090%0.169+24%0.442-53%0.442-53%
Debt To Equity Ratio--0.2640.2640%0.203+30%1.354-81%1.354-81%
Dividend Per Share--31.49731.4970%10.500+200%15.749+100%15.749+100%
Eps--38.11138.1110%34.174+12%31.633+20%31.633+20%
Free Cash Flow Per Share--11.68811.6880%37.984-69%21.885-47%21.885-47%
Free Cash Flow To Equity Per Share---19.945-19.9450%31.554-163%5.220-482%5.220-482%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--214.754--------
Intrinsic Value_10Y_min--185.325--------
Intrinsic Value_1Y_max--24.514--------
Intrinsic Value_1Y_min--23.820--------
Intrinsic Value_3Y_max--71.372--------
Intrinsic Value_3Y_min--67.447--------
Intrinsic Value_5Y_max--115.480--------
Intrinsic Value_5Y_min--106.221--------
Market Cap92158683050.000+48%47981640555.20047981640555.2000%56239971948.000-15%26055403125.800+84%26055403125.800+84%
Net Profit Margin--0.2160.2160%0.197+10%0.201+8%0.201+8%
Operating Margin--0.2780.2780%0.273+2%0.284-2%0.284-2%
Operating Ratio--1.1921.1920%1.219-2%1.188+0%1.188+0%
Pb Ratio4.310+48%2.2442.2440%2.738-18%1.245+80%1.245+80%
Pe Ratio19.736+48%10.27510.2750%13.431-23%5.927+73%5.927+73%
Price Per Share752.150+48%391.600391.6000%459.000-15%212.650+84%212.650+84%
Price To Free Cash Flow Ratio64.353+48%33.50533.5050%12.084+177%11.397+194%11.397+194%
Price To Total Gains Ratio19.616+48%10.21310.2130%3.932+160%7.073+44%7.073+44%
Quick Ratio--1.7911.7910%1.767+1%1.154+55%1.154+55%
Return On Assets--0.1730.1730%0.169+2%0.175-1%0.175-1%
Return On Equity--0.2180.2180%0.204+7%0.417-48%0.417-48%
Total Gains Per Share--38.34438.3440%116.727-67%59.376-35%59.376-35%
Usd Book Value--256584840.000256584840.0000%246517440.000+4%160408740.000+60%160408740.000+60%
Usd Book Value Change Per Share--0.0820.0820%1.275-94%0.524-84%0.524-84%
Usd Book Value Per Share--2.0942.0940%2.012+4%1.309+60%1.309+60%
Usd Dividend Per Share--0.3780.3780%0.126+200%0.189+100%0.189+100%
Usd Eps--0.4570.4570%0.410+12%0.380+20%0.380+20%
Usd Free Cash Flow--17184960.00017184960.0000%55849560.000-69%32177460.000-47%32177460.000-47%
Usd Free Cash Flow Per Share--0.1400.1400%0.456-69%0.263-47%0.263-47%
Usd Free Cash Flow To Equity Per Share---0.239-0.2390%0.379-163%0.063-482%0.063-482%
Usd Market Cap1105904196.600+48%575779686.662575779686.6620%674879663.376-15%312664837.510+84%312664837.510+84%
Usd Price Per Share9.026+48%4.6994.6990%5.508-15%2.552+84%2.552+84%
Usd Profit--56035320.00056035320.0000%50246880.000+12%46510920.000+20%46510920.000+20%
Usd Revenue--259346400.000259346400.0000%254785680.000+2%231207360.000+12%231207360.000+12%
Usd Total Gains Per Share--0.4600.4600%1.401-67%0.713-35%0.713-35%
 EOD+4 -4MRQTTM+0 -0YOY+19 -165Y+18 -1710Y+18 -17

3.2. Fundamental Score

Let's check the fundamental score of Glenmark Life Sciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1519.736
Price to Book Ratio (EOD)Between0-14.310
Net Profit Margin (MRQ)Greater than00.216
Operating Margin (MRQ)Greater than00.278
Quick Ratio (MRQ)Greater than11.791
Current Ratio (MRQ)Greater than13.668
Debt to Asset Ratio (MRQ)Less than10.209
Debt to Equity Ratio (MRQ)Less than10.264
Return on Equity (MRQ)Greater than0.150.218
Return on Assets (MRQ)Greater than0.050.173
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Glenmark Life Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.803
Ma 20Greater thanMa 50800.115
Ma 50Greater thanMa 100808.079
Ma 100Greater thanMa 200766.448
OpenGreater thanClose812.800
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets27,021,470
Total Liabilities5,639,400
Total Stockholder Equity21,382,070
 As reported
Total Liabilities 5,639,400
Total Stockholder Equity+ 21,382,070
Total Assets = 27,021,470

Assets

Total Assets27,021,470
Total Current Assets18,503,390
Long-term Assets8,518,080
Total Current Assets
Cash And Cash Equivalents 2,838,230
Short-term Investments 964,780
Net Receivables 8,067,660
Inventory 6,041,710
Other Current Assets 845,010
Total Current Assets  (as reported)18,503,390
Total Current Assets  (calculated)18,757,390
+/- 254,000
Long-term Assets
Property Plant Equipment 8,242,440
Intangible Assets 180,010
Other Assets 94,860
Long-term Assets  (as reported)8,518,080
Long-term Assets  (calculated)8,517,310
+/- 770

Liabilities & Shareholders' Equity

Total Current Liabilities5,044,140
Long-term Liabilities595,260
Total Stockholder Equity21,382,070
Total Current Liabilities
Accounts payable 3,965,610
Other Current Liabilities 220,530
Total Current Liabilities  (as reported)5,044,140
Total Current Liabilities  (calculated)4,186,140
+/- 858,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt193,570
Other Liabilities 424,340
Long-term Liabilities  (as reported)595,260
Long-term Liabilities  (calculated)617,910
+/- 22,650
Total Stockholder Equity
Common Stock245,050
Other Stockholders Equity 21,137,020
Total Stockholder Equity (as reported)21,382,070
Total Stockholder Equity (calculated)21,382,070
+/-0
Other
Capital Stock245,050
Common Stock Shares Outstanding 122,527
Net Invested Capital 21,382,070
Net Tangible Assets 21,202,060
Net Working Capital 13,459,250
Property Plant and Equipment Gross 8,242,440



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-31
> Total Assets 
17,256,040
19,970,750
24,710,070
27,021,470
27,021,47024,710,07019,970,75017,256,040
   > Total Current Assets 
11,601,140
13,990,410
17,645,840
18,503,390
18,503,39017,645,84013,990,41011,601,140
       Cash And Cash Equivalents 
99,980
1,155,960
5,121,570
2,838,230
2,838,2305,121,5701,155,96099,980
       Short-term Investments 
207,700
241,640
51,460
964,780
964,78051,460241,640207,700
       Net Receivables 
6,720,050
6,195,000
6,734,870
8,067,660
8,067,6606,734,8706,195,0006,720,050
       Inventory 
4,127,750
5,134,210
5,162,440
6,041,710
6,041,7105,162,4405,134,2104,127,750
       Other Current Assets 
650,010
774,080
566,280
845,010
845,010566,280774,080650,010
   > Long-term Assets 
5,654,900
5,980,340
7,064,230
8,518,080
8,518,0807,064,2305,980,3405,654,900
       Property Plant Equipment 
5,498,080
5,789,860
6,763,360
8,242,440
8,242,4406,763,3605,789,8605,498,080
       Intangible Assets 
71,680
79,110
103,800
180,010
180,010103,80079,11071,680
       Other Assets 
84,370
110,600
196,300
94,860
94,860196,300110,60084,370
> Total Liabilities 
13,239,120
12,443,280
4,166,950
5,639,400
5,639,4004,166,95012,443,28013,239,120
   > Total Current Liabilities 
13,074,640
12,214,400
3,839,960
5,044,140
5,044,1403,839,96012,214,40013,074,640
       Short Long Term Debt 
210
0
0
0
000210
       Accounts payable 
2,010,710
2,213,050
3,077,180
3,965,610
3,965,6103,077,1802,213,0502,010,710
       Other Current Liabilities 
161,660
255,130
298,220
220,530
220,530298,220255,130161,660
   > Long-term Liabilities 
164,480
228,880
326,990
595,260
595,260326,990228,880164,480
       Other Liabilities 
164,480
228,880
314,950
424,340
424,340314,950228,880164,480
> Total Stockholder Equity
4,016,920
7,527,470
20,543,120
21,382,070
21,382,07020,543,1207,527,4704,016,920
   Common Stock
19,600
19,600
245,050
245,050
245,050245,05019,60019,600
   Retained Earnings Total Equity0000
   Accumulated Other Comprehensive Income 0000
   Capital Surplus 0000
   Treasury Stock0000
   Other Stockholders Equity 
3,997,320
7,507,870
20,298,070
21,137,020
21,137,02020,298,0707,507,8703,997,320



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue21,612,200
Cost of Revenue-10,140,880
Gross Profit11,471,32011,471,320
 
Operating Income (+$)
Gross Profit11,471,320
Operating Expense-15,610,210
Operating Income6,001,990-4,138,890
 
Operating Expense (+$)
Research Development0
Selling General Administrative337,680
Selling And Marketing Expenses0
Operating Expense15,610,210337,680
 
Net Interest Income (+$)
Interest Income157,660
Interest Expense-5,470
Other Finance Cost-157,660
Net Interest Income-5,470
 
Pretax Income (+$)
Operating Income6,001,990
Net Interest Income-5,470
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,286,0906,001,990
EBIT - interestExpense = 6,002,100
6,286,090
4,675,080
Interest Expense5,470
Earnings Before Interest and Taxes (EBIT)6,007,5706,291,560
Earnings Before Interest and Taxes (EBITDA)6,712,500
 
After tax Income (+$)
Income Before Tax6,286,090
Tax Provision-1,616,480
Net Income From Continuing Ops4,669,6104,669,610
Net Income4,669,610
Net Income Applicable To Common Shares4,669,610
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,819,080
Total Other Income/Expenses Net05,470
 

Technical Analysis of Glenmark Life Sciences Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Glenmark Life Sciences Ltd. The general trend of Glenmark Life Sciences Ltd is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Glenmark Life Sciences Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Glenmark Life Sciences Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 904.20.

The bearish price targets are: 768.75 > 751.05 > 666.05.

Tweet this
Glenmark Life Sciences Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Glenmark Life Sciences Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Glenmark Life Sciences Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Glenmark Life Sciences Ltd. The current macd is 3.86893727.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Glenmark Life Sciences Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Glenmark Life Sciences Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Glenmark Life Sciences Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Glenmark Life Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGlenmark Life Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Glenmark Life Sciences Ltd. The current adx is 20.26.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Glenmark Life Sciences Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Glenmark Life Sciences Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Glenmark Life Sciences Ltd. The current sar is 856.20.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Glenmark Life Sciences Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Glenmark Life Sciences Ltd. The current rsi is 38.80. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Glenmark Life Sciences Ltd Daily Relative Strength Index (RSI) ChartGlenmark Life Sciences Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Glenmark Life Sciences Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Glenmark Life Sciences Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Glenmark Life Sciences Ltd Daily Stochastic Oscillator ChartGlenmark Life Sciences Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Glenmark Life Sciences Ltd. The current cci is -87.81385082.

Glenmark Life Sciences Ltd Daily Commodity Channel Index (CCI) ChartGlenmark Life Sciences Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Glenmark Life Sciences Ltd. The current cmo is -34.23103557.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Glenmark Life Sciences Ltd Daily Chande Momentum Oscillator (CMO) ChartGlenmark Life Sciences Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Glenmark Life Sciences Ltd. The current willr is -92.40674956.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Glenmark Life Sciences Ltd Daily Williams %R ChartGlenmark Life Sciences Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Glenmark Life Sciences Ltd. The current atr is 34.39.

Glenmark Life Sciences Ltd Daily Average True Range (ATR) ChartGlenmark Life Sciences Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Glenmark Life Sciences Ltd. The current obv is 2,391,071.

Glenmark Life Sciences Ltd Daily On-Balance Volume (OBV) ChartGlenmark Life Sciences Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Glenmark Life Sciences Ltd. The current mfi is 46.81.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Glenmark Life Sciences Ltd Daily Money Flow Index (MFI) ChartGlenmark Life Sciences Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Glenmark Life Sciences Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Glenmark Life Sciences Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Glenmark Life Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.803
Ma 20Greater thanMa 50800.115
Ma 50Greater thanMa 100808.079
Ma 100Greater thanMa 200766.448
OpenGreater thanClose812.800
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Glenmark Life Sciences Ltd with someone you think should read this too:
  • Are you bullish or bearish on Glenmark Life Sciences Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Glenmark Life Sciences Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Glenmark Life Sciences Ltd

I send you an email if I find something interesting about Glenmark Life Sciences Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Glenmark Life Sciences Ltd.

Receive notifications about Glenmark Life Sciences Ltd in your mailbox!